[1. Kemp CD, Conte JV. The pathophysiology of heart failure. Cardiovasc Pathol. 2012;21:365-371. doi: 10.1016/j.carpath.2011.11.007.10.1016/j.carpath.2011.11.00722227365]Open DOISearch in Google Scholar
[2. Lloyd-Jones DM, Larson MG, Leip EP, et al. Lifetime Risk for Developing Congestive Heart Failure. Circulation. 2002;106:3068-3072. doi: 10.1161/01.CIR.0000039105.49749.6F.10.1161/01.CIR.0000039105.49749.6]Open DOISearch in Google Scholar
[3. Bredy C, Ministeri M, Kempny A, et al. New York Heart Association (NYHA) classification in adults with congenital heart disease: relation to objective measures of exercise and outcome. Eur Heart J Qual Care Clin Outcomes. 2018;4:51-58. doi: 10.1093/ehjqcco/qcx031.10.1093/ehjqcco/qcx03128950356]Open DOISearch in Google Scholar
[4. Chioncel O, Tatu-Chitoiu G, Christodorescu R, et al. Characteristics of patients with heart failure from Romania enrolled in - ESC-HF Long-Term (ESC-HF-LT) Registry. Romanian Journal of Cardiology. 2015;25:413-420.]Search in Google Scholar
[5. Sinescu C, Axente L. Heart failure – concepts and significance. Birth of a prognostic model. J Med Life. 2010;3:421-429.]Search in Google Scholar
[6. Pop D, Penciu OM, Sitar-Taut AV, Zdrenghea DT. Comparative heart failure profile over a 3-year period in a Romanian general hospital. Clin Interv Aging. 2013;8:999-1005. doi: 10.2147/CIA.S46760.10.2147/CIA.S46760373387323930074]Search in Google Scholar
[7. Klip IT, Comin-Colet J, Voors AA, et al. Iron deficiency in chronic heart failure: An international pooled analysis. Am Heart J. 2013;165:575-82.e3. doi: 10.1016/j.ahj.2013.01.017.10.1016/j.ahj.2013.01.01723537975]Open DOISearch in Google Scholar
[8. Cleland JGF, Zhang J, Pellicori P, et al. Prevalence and Outcomes of Anemia and Hematinic Deficiencies in Patients With Chronic Heart Failure. JAMA Cardiol. 2016;1:539-547. doi: 10.1001/jamacardio.2016.1161.10.1001/jamacardio.2016.116127439011]Search in Google Scholar
[9. Okonko DO, Mandal AKJ, Missouris CG, Poole-Wilson PA. Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival. J Am Coll Cardiol. 2011;58:1241-1251. doi: 10.1016/j.jacc.2011.04.040.10.1016/j.jacc.2011.04.04021903058]Open DOISearch in Google Scholar
[10. Jankowska EA, Rozentryt P, Witkowska A, et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J. 2010;31:1872-1880. doi: 10.1093/eurheartj/ehq158.10.1093/eurheartj/ehq15820570952]Search in Google Scholar
[11. Comín-Colet J, Enjuanes C, González G, et al. Iron deficiency is a key determinant of health-related quality of life in patients with chronic heart failure regardless of anaemia status. Eur J Heart Fail. 2013;15:1164-1172. doi: 10.1093/eurjhf/hft083.10.1093/eurjhf/hft083378214623703106]Open DOISearch in Google Scholar
[12. Dalal J, Katekhaye V, Jain R. Effect of ferric carboxymaltose on hospitalization and mortality outcomes in chronic heart failure: A meta-analysis. Indian Heart J. 2017;69:736-741. doi: 10.1016/j.ihj.2017.10.009.10.1016/j.ihj.2017.10.009571730029174251]Open DOISearch in Google Scholar
[13. Anker SD, Comín-Colet J, Filippatos G, et al. Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency. N Engl J Med. 2009;361:2436-2448. doi: 10.1056/NEJMoa0908355.10.1056/NEJMoa090835519920054]Open DOISearch in Google Scholar
[14. Ponikowski P, van Veldhuisen DJ, Comín-Colet J, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2015;36:657-668. doi: 10.1093/eurheartj/ehu385.10.1093/eurheartj/ehu385435935925176939]Open DOISearch in Google Scholar
[15. Hotărârea de Guvern nr. Nr. 140/2018 din 21 martie 2018 publicată în Monitorul Oficial al României Partea I, nr. 270 din 27 martie 2018. Available at: http://www.casan.ro/casalba/media/postFiles/HG%20140-CONTRACT%20CADRU%202018-2019.pdf]Search in Google Scholar
[16. Ordinul ministrului sănătății și al președintelui Casei Naționale de Asigurări de Sănătate nr. 397/836/2018 privind aprobarea Normelor metodologice de aplicare în anul 2018 a Hotărârii Guvernului nr. 140/2018 pentru aprobarea pachetelor de servicii și a Contractului-cadru care reglementează condițiile acordării asistenței medicale, a medicamentelor și a dispozitivelor medicale în cadrul sistemului de asigurări sociale de sănătate pentru anii 2018-2019. Available at: http://www.cnas.ro/casgorj/media/postFiles/Ordin%20397-836_2018%20(actualizat%20cu%20Ordin%20MS-CNAS%20910-1161_2018).pdf]Search in Google Scholar
[17. Theidel U, Väätäinen S, Martikainen J, Soini E, Hardt T, Doehner W. Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany. ESC heart failure. 2017;4:274-281. doi: 10.1002/ehf2.12179.10.1002/ehf2.12179554273128772041]Open DOISearch in Google Scholar
[18. Bourguignon S, Faller M, Champs F-O, et al. Budget impact of intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency in France. ESC Heart Fail. 2019;6:559-569. doi: 10.1002/ehf2.12432.10.1002/ehf2.12432648771731021531]Open DOISearch in Google Scholar
[19. Ressl S, Walter E, Bauer M. Budget-Impact-Analysis Of Iron Treatment Using Intravenous Ferric Carboxymaltose In Patients With Chronic Heart Failure And Iron Deficiency In Austria. Value Health. 2015;18:A384. doi: 10.1016/j.jval.2015.09.831.10.1016/j.jval.2015.09.831]Open DOISearch in Google Scholar
[20. Walter E, Bauer M, Ressl S. Cost-Effectiveness Of Ferric Carboxymaltose In Patients With Iron Deficiency And Chronic Heart Failure In Austria. Value Health. 2015;18:A392. doi: 10.1016/j.jval.2015.09.876.10.1016/j.jval.2015.09.876]Open DOISearch in Google Scholar
[21. Gutzwiller FS, Schwenkglenks M, Blank PR, et al. Health economic assessment of ferric carboxymaltose in patients with iron deficiency and chronic heart failure based on the FAIR-HF trial: an analysis for the UK. Eur J Heart Fail. 2012;14:782-790. doi: 10.1093/eurjhf/hfs083.10.1093/eurjhf/hfs083338054622689292]Open DOISearch in Google Scholar
[22. Comín-Colet J, Rubio-Rodríguez D, Rubio-Terrés C, et al. A Cost-effectiveness Analysis of Ferric Carboxymaltose in Patients With Iron Deficiency and Chronic Heart Failure in Spain. Rev Esp Cardiol (Engl Ed). 2015;68:846-851. doi: 10.1016/j.rec.2014.10.010.10.1016/j.rec.2014.10.01025649970]Open DOISearch in Google Scholar
[23. Hofmarcher T, Borg S. Cost-effectiveness analysis of ferric carboxymaltose in iron-deficient patients with chronic heart failure in Sweden. J Med Econ. 2015;18:492-501. doi: 10.3111/13696998.2015.1029491.10.3111/13696998.2015.102949125766863]Open DOISearch in Google Scholar
[24. Mylonas C, Kourlaba G, Berberian K, Maniadakis N. Economic Evaluation Of Ferric Carboxymaltose In Patients With Chronic Heart Failure And Iron Deficiency: An Analysis For Greece Based On Fair-Hf Trial. Value Health. 2014;17:A486. doi: 10.1016/j.jval.2014.08.1424.10.1016/j.jval.2014.08.142427201432]Open DOISearch in Google Scholar
[25. Lim EA, Sohn HS, Lee H, Choi SE. Cost-utility of ferric carboxymaltose (Ferinject®) for iron-deficiency anemia patients with chronic heart failure in South Korea. Cost effectiveness and resource allocation: C/E. 2014;12:19. doi: 10.1186/1478-7547-12-19.10.1186/1478-7547-12-19416657425278814]Open DOISearch in Google Scholar
[26. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129-2200. doi: 10.1002/ejhf.592.10.1002/ejhf.59227207191]Open DOISearch in Google Scholar